摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(4-ethylbenzyl)-4-(β-D-glucopyranos-1-yl)-2-methoxy-benzonitrile | 1022984-17-3

中文名称
——
中文别名
——
英文名称
6-(4-ethylbenzyl)-4-(β-D-glucopyranos-1-yl)-2-methoxy-benzonitrile
英文别名
2-[(4-ethylphenyl)methyl]-6-methoxy-4-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]benzonitrile
6-(4-ethylbenzyl)-4-(β-D-glucopyranos-1-yl)-2-methoxy-benzonitrile化学式
CAS
1022984-17-3
化学式
C23H27NO6
mdl
——
分子量
413.47
InChiKey
GOVGDQOFOBALQP-ZQGJOIPISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    30
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    123
  • 氢给体数:
    4
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    6-(4-ethylbenzyl)-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-2-methoxybenzonitrile 、 sodium hydroxide 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 1.0h, 以57%的产率得到6-(4-ethylbenzyl)-4-(β-D-glucopyranos-1-yl)-2-methoxy-benzonitrile
    参考文献:
    名称:
    PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE
    摘要:
    该发明涉及根据权利要求1的药物组合物,包括一种葡萄糖吡喃基取代苯衍生物与一种适用于治疗或预防从以下选定的一种或多种疾病的DPP IV抑制剂的组合物,所述疾病包括1型糖尿病、2型糖尿病、糖耐量受损和高血糖。此外,本发明涉及预防或治疗代谢紊乱及相关疾病的方法。
    公开号:
    EP3939577A1
点击查看最新优质反应信息

文献信息

  • GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZONITRILE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE
    申请人:Himmelsbach Frank
    公开号:US20100069310A1
    公开(公告)日:2010-03-18
    Glucopyranosyl-substituted benzyl-benzonitrile derivatives of general formula (I) as defined according to claim 1 , including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
    通式(I)中含有葡萄糖喃基取代的苯基苯甲腈生物,如权利要求1所定义,包括其互变异构体、立体异构体、混合物和盐。本发明的化合物适用于治疗代谢性疾病。
  • PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE
    申请人:Dugi Klaus
    公开号:US20110195917A1
    公开(公告)日:2011-08-11
    The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    该发明涉及一种药物组合物,根据权利要求1,包括一种葡萄糖喃基取代的苯衍生物和一种适用于治疗或预防从以下选择的一种或多种疾病的DPP IV抑制剂:1型糖尿病,2型糖尿病,糖耐量受损和高血糖。此外,本发明还涉及预防或治疗代谢紊乱和相关疾病的方法。
  • Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
    申请人:Boehringer Ingelheim International GmbH
    公开号:EP2698152A1
    公开(公告)日:2014-02-19
    The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    本发明涉及根据权利要求1所述的药物组合物,该药物组合物由葡糖喃糖基取代的苯衍生物DPP IV抑制剂组合而成,适用于治疗或预防选自1型糖尿病、2型糖尿病、糖耐量受损和高血糖症的一种或多种病症。此外,本发明还涉及预防或治疗代谢紊乱及相关疾病的方法。
  • PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF
    申请人:Boehringer Ingelheim International GmbH
    公开号:EP3150200A1
    公开(公告)日:2017-04-05
    The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
    本发明涉及由一种 SGLT-2 抑制剂药物和一种伙伴药物的固定剂量组合物组成的药物组合物、其制备工艺及其用于治疗某些疾病的用途。
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    申请人:Boehringer Ingelheim International GmbH
    公开号:EP3539540A1
    公开(公告)日:2019-09-18
    The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions
    本发明涉及根据权利要求1所述的药物组合物,该药物组合物由SGLT2抑制剂胰岛素组成,适用于治疗或预防选自1型糖尿病、2型糖尿病、糖耐量受损和高血糖症的一种或多种病症。此外,本发明还涉及预防或治疗代谢紊乱及相关疾病的方法。
查看更多